Mezagitamab

Verified

Overview

Mezagitamab (TAK-079) is a fully human, non-agonistic, IgG1 cell-depleting monoclonal antibody that binds human CD38 with high affinity.

SparkCures ID 310
Developed By Takeda Oncology
Generic Name Mezagitamab
Additional Names TAK-079
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

November 13, 2019

In the 14 patients receiving at least 4 cycles of therapy by the time of the data cutoff, the objective response rate (ORR; partial response or better) was 43%, 1 patient's response deepened over time to VGPR, the clinical benefit rate (minimal response or better) was 57%. Within this group, in patients never exposed to anti-CD38 therapy, the ORR was 46%.

Resources

There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Takeda Oncology to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners